| Literature DB >> 31092896 |
Yasuharu Sato1,2, Hiroaki Miyoshi3, Kana Sakamoto4, Yosaku Watatani5, Kenji Nishida1, Yuka Gion2, Yasunobu Nagata5, Yuichi Shiraishi6, Kenichi Chiba6, Hiroko Tanaka6, Lanying Zhao5, Yotaro Ochi5, Yasuhide Takeuchi5, June Takeda5, Hiroo Ueno5, Yasunori Kogure5,7, Yusuke Shiozawa5, Nobuyuki Kakiuchi5, Tetsuichi Yoshizato5, Masahiro M Nakagawa5, Yasuhito Nanya5, Kenichi Yoshida5, Hideki Makishima5, Masashi Sanada8, Mamiko Sakata-Yanagimoto9, Shigeru Chiba9, Ryota Matsuoka10, Masayuki Noguchi10, Nobuhiro Hiramoto11, Takayuki Ishikawa11, Junichi Kitagawa12, Nobuhiko Nakamura12, Hisashi Tsurumi12, Tatsuhiko Miyazaki13, Yusuke Kito14, Satoru Miyano6, Kazuya Shimoda15, Kengo Takeuchi4,16, Koichi Ohshima3, Tadashi Yoshino1, Seishi Ogawa17, Keisuke Kataoka18,19.
Abstract
Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) is a diagnosis of exclusion, being the most common entity in mature T-cell neoplasms, and its molecular pathogenesis remains significantly understudied. Here, combining whole-exome and targeted-capture sequencing, gene-expression profiling, and immunohistochemical analysis of tumor samples from 133 cases, we have delineated the entire landscape of somatic alterations, and discovered frequently affected driver pathways in PTCL, NOS, with and without a T-follicular helper (TFH) cell phenotype. In addition to previously reported mutational targets, we identified a number of novel recurrently altered genes, such as KMT2C, SETD1B, YTHDF2, and PDCD1. We integrated these genetic drivers using hierarchical clustering and identified a previously undescribed molecular subtype characterized by TP53 and/or CDKN2A mutations and deletions in non-TFH PTCL, NOS. This subtype exhibited different prognosis and unique genetic features associated with extensive chromosomal instability, which preferentially affected molecules involved in immune escape and transcriptional regulation, such as HLA-A/B and IKZF2. Taken together, our findings provide novel insights into the molecular pathogenesis of PTCL, NOS by highlighting their genetic heterogeneity. These results should help to devise a novel molecular classification of PTCLs and to exploit a new therapeutic strategy for this group of aggressive malignancies.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31092896 DOI: 10.1038/s41375-019-0473-1
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528